Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Reviva Pharmaceuticals Holdings, Inc. RVPH

Healthcare Biotechnology
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system and respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug... see more

Recent & Breaking News (NDAQ:RVPH)

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

GlobeNewswire November 14, 2023

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

GlobeNewswire October 30, 2023

Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

Accesswire September 29, 2023

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

GlobeNewswire September 25, 2023

Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

Accesswire September 22, 2023

Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 7, 2023

Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia

GlobeNewswire August 17, 2023

Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights

GlobeNewswire August 14, 2023

RedChip Launches 'Small Stocks, Big Money' Podcast

Accesswire August 2, 2023

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August

GlobeNewswire July 31, 2023

Reviva Pharmaceuticals to be Added to Russell Microcap® Index

GlobeNewswire June 26, 2023

Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia

GlobeNewswire June 22, 2023

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in June

GlobeNewswire June 15, 2023

Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives

GlobeNewswire May 25, 2023

Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting

GlobeNewswire May 22, 2023

Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform

GlobeNewswire May 19, 2023

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023

GlobeNewswire May 18, 2023

Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights

GlobeNewswire May 15, 2023

Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

GlobeNewswire May 12, 2023

Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data

GlobeNewswire May 11, 2023